TSMHT
CATX icon

Thurston Springer Miller Herd & Titak’s Perspective Therapeutics CATX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-117
Closed -$402 – 660
2025
Q2 		$402 Hold
117
– – ﹤0.01% 1569
2025
Q1 		$249 Buy
+117
New +$351 ﹤0.01% 1624

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's CATX Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Perspective Therapeutics (CATX) in Q3 2025, closing a stake of 117 shares — an estimated $402 sold.

Thurston Springer Miller Herd & Titak first reported a position in CATX in Q1 2025 and held it in 2 quarters. The position peaked at $402 in Q2 2025. 105 funds tracked by Wall St. Rank hold CATX as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Perspective Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 117 Perspective Therapeutics shares in Q3 2025, an estimated $402.
  • Thurston Springer Miller Herd & Titak first reported a position in Perspective Therapeutics in Q1 2025 and held it in 2 quarters.
  • Thurston Springer Miller Herd & Titak's Perspective Therapeutics position peaked at $402 in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.